Electrophysiological and clinical correlations in the Lambert-Eaton myasthenic syndrome
β Scribed by Shin J. Oh; Doo E. Kim; Reha Kuruoglu; Jordan Brooks; Gwendolyn Claussen
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 273 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0148-639X
No coin nor oath required. For personal study only.
β¦ Synopsis
has not been any report which studied systematically the relationship between the repetitive nerve stimulation (RNS) test and severity of Lambert-Eaton myasthenic syndrome (LEMS) . We report such a study here.
Methods
This study was based on 57 RNS tests on the abductor digiti quinti (ADO muscle and 37 RNS tests on the flexor carpi ulnaris (FCU) muscle in 19 patients with LEMS. There were 11 men and 8 women. Ages ranged from 28 to 75 years. A tumor was found in 14 (74%) of the cases. Except for 1 patient with thyroid carcinoma and 1 with mediastinal germinoma, all other patients had small cell carcinoma of the lung. The diagnosis of LEMS was based on clinical features (easy fatigability, proximal leg weakness, and diminished or absent muscle stretch reflexes) and the classic triad on the RNS test [low compound muscle action potential (CMAP) amplitude, abnormal decremental response (> 7%) at low rate of stimulation (LRS), and adnormal incremental response (> 100%) at high rate of stimulation (HRS)] .3,5
The RNS test was performed in the ADQ and FCU muscles with stimulation of ulnar nerve at elbow and the data were analyzed following the previously described m e t h ~d . ~ Tests include the CMAP at rest and after 30-s exercise, the responses at the low rate (2-5/s) as well as the high rate (50,'s) of stimulation,
π SIMILAR VOLUMES
A patient with LEMS unrelated to cancer was studied by ## CASE OF THE MONTH stimulated single-fiber electromyography (SFEMG) before and 3 months after the onset of therapy with 3,4-diaminopyridine. All end-plates showed Section Editors a progressive reduction in blockings and jitter with the incr
The high incidence of elevated immunoglobulin (Ig)G anti-GQ1b antibody in sera from patients with acute phase Miller-Fisher syndrome (MFS) was first reported by Chiba et al. 1 and later confirmed by two other groups. 3,4 Chiba et al. 2 pointed out that anti-GQ1b IgG antibody is associated specifical